82 related articles for article (PubMed ID: 20569983)
1. Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes.
Akiyama N; Miyazawa K; Kanda Y; Tohyama K; Omine M; Mitani K; Ohyashiki K
Leuk Res; 2010 Sep; 34(9):1151-7. PubMed ID: 20569983
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment of leukemia cells with vitamin K2 and 1alpha,25-dihydroxy vitamin D3 enhances monocytic differentiation along with becoming resistant to apoptosis by induction of cytoplasmic p21CIP1.
Iguchi T; Miyazawa K; Asada M; Gotoh A; Mizutani S; Ohyashiki K
Int J Oncol; 2005 Oct; 27(4):893-900. PubMed ID: 16142303
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
4. Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome.
Takami A; Asakura H; Nakao S
Ann Hematol; 2002 Jan; 81(1):16-9. PubMed ID: 11807630
[TBL] [Abstract][Full Text] [Related]
5. [Vitamin K2 therapy for myelodysplastic syndrome].
Abe Y; Muta K; Hirase N; Choi I; Matsushima T; Hara K; Taguchi F; Suematsu E; Shibata K; Uike N; Nishimura J; Nawata H
Rinsho Ketsueki; 2002 Feb; 43(2):117-21. PubMed ID: 11925874
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
[TBL] [Abstract][Full Text] [Related]
7. [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome].
Lu XC; Yang B; Zhu HL; Fan H; Li SX; Liu Y; Yao SQ
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1834-7. PubMed ID: 19953928
[TBL] [Abstract][Full Text] [Related]
8. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
9. Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages.
Sada E; Abe Y; Ohba R; Tachikawa Y; Nagasawa E; Shiratsuchi M; Takayanagi R
Eur J Haematol; 2010 Dec; 85(6):538-48. PubMed ID: 20887388
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study.
Xiao Z; Xu Z; Zhang Y; Qin T; Zhang H; Fang L
Leuk Res; 2011 Jan; 35(1):61-5. PubMed ID: 20591481
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
13. Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.
Itzykson R; Ayari S; Vassilief D; Berger E; Slama B; Vey N; Suarez F; Beyne-Rauzy O; Guerci A; Cheze S; Thomas X; Stamatoullas A; Gardembas M; Bauduer F; Kolb A; Chaury MC; Legros L; Damaj G; Chermat F; Dreyfus F; Fenaux P; Ades L;
Leukemia; 2009 Apr; 23(4):673-8. PubMed ID: 19151787
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemias and myeloproliferative disorders].
Takahashi T; Ichiba S; Okuno Y; Sugiyama H; Sakai Y; Imura H; Iho S; Hoshino T; Suzuki A; Okada T
Rinsho Ketsueki; 1989 Jan; 30(1):1-10. PubMed ID: 2716194
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
16. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Kantarjian H
Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
18. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
Raza A; Galili N; Smith SE; Godwin J; Boccia RV; Myint H; Mahadevan D; Mulford D; Rarick M; Brown GL; Schaar D; Faderl S; Komrokji RS; List AF; Sekeres M
Cancer; 2012 Apr; 118(8):2138-47. PubMed ID: 21887679
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis induction of vitamin K2 in lung carcinoma cell lines: the possibility of vitamin K2 therapy for lung cancer.
Yoshida T; Miyazawa K; Kasuga I; Yokoyama T; Minemura K; Ustumi K; Aoshima M; Ohyashiki K
Int J Oncol; 2003 Sep; 23(3):627-32. PubMed ID: 12888897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
